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In addition to locally controlling the tumor, hypofractionated radiotherapy (RT) particu-
larly aims to activate immune cells in the RT-modified microenvironment. Therefore, we 
examined whether hypofractionated RT can activate dendritic cells (DCs), induce immune 
cell infiltration in tumors, and how the chronology of immune cell migration into tumors 
occurs to gain knowledge for future definition of radiation breaks and inclusion of immu-
notherapy. Colorectal cancer treatments offer only limited survival benefit, and immuno-
biological principles for additional therapies need to be explored with preclinical models. 
The impact of hypofractionated RT on CT26 colon cancer tumor cell death, migration of 
DCs toward supernatants (SN) of tumor cells, and activation of DCs by SN were analyzed. 
The subcutaneous tumor of a BALB/c-CT26 mouse model was locally irradiated with 
2 × 5 Gy, the tumor volume was monitored, and the infiltration of immune cells in the 
tumor was determined by flow cytometry daily. Hypofractionated RT induced a mixture of 
apoptotic and necrotic CT26 cells, which is known to be in particular immunogenic. DCs 
that migrated toward SN of CT26 cells particularly upregulated the activation markers 
CD80 and CD86 when in contact with SN of irradiated tumor cells. After hypofraction-
ated RT, the tumor outgrowth was significantly retarded and in the irradiated tumors an 
increased infiltration of macrophages (CD11bhigh/F4-80+) and DCs (MHC-II+), but only 
between day 5 and 10 after the first irradiation, takes place. While CD4+ T cells migrated 
into non-irradiated and irradiated tumors, CD8 + T cells were only found in tumors that 
had been irradiated and they were highly increased at day 8 after the first irradiation. 
Myeloid-derived suppressor cells and regulatory T cells show regular turnover in irradiated 
and non-irradiated tumors. T umor cell-specific anti-IgM antibodies were enhanced in the 
serum of animals with irradiated tumors. We conclude that hypofractionated RT suffices 
to activate DCs and to induce infiltration of innate and adaptive immune cells into solid 
colorectal tumors. However, the presence of immune cells in the tumor which are beneficial 
for antitumor immune responses is timely restricted. These findings should be considered 
when innovative multimodal tumor treatment protocols of distinct RT with immune thera-
pies are designed and clinically implemented.
Keywords: hypofractionated radiotherapy, colorectal cancer, tumor-infiltrating immune cells, macrophages, 
antigen-presenting cells, cD8+ T cell, tumor cell-specific igM, immunogenic radiotherapy
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inTrODUcTiOn
A promising treatment strategy for solid tumors is the combination 
of classical tumor therapies namely surgery, radiotherapy (RT), 
and chemotherapy (CT) with immunotherapy (IT) (1). There is a 
strong need for rational and well-deliberated approaches of RT–
drug combinations on the basis of the molecular understanding 
of radiobiology and immunology (2–4) since knowledge about 
the most beneficial time point for radiation breaks and inclusion 
of IT is scarce.
In high-income countries, more than 50% of cancer patients 
receive RT as part of their tumor treatment (5). RT induces 
DNA damage that results in tumor cell cycle arrest and ideally in 
tumor cell death. The applied amount of radiation is measured 
in gray (Gy) and aside from the total irradiation dose, the dose 
fractionation has a substantial impact on therapy outcome. A 
conventional fractionation scheme comprises 1.8–2.2  Gy per 
day, five times a week. Although different variations of RT 
have been clinically evaluated and are now standard options. 
While hyperfractionated regimens deliver a high number of 
small treatment doses (0.5–2.2  Gy per day), hypofractiona-
tion consists of less fractions with increased doses (3–20  Gy 
per day) (6) and the latter is considered as being particularly 
immunogenic (7).
Aside from the effect of RT on DNA, it can also influence 
immunological responses (8). This can help to fight the tumor 
locally and at distant, metastasized sites. The regression of tumors 
distant from the radiation field was named abscopal effect by Mole 
(9). With the advanced understanding of the immune system’s 
role in radiation biology, it is hypothesized that such effects are 
due to a systemic antitumor immune response. One fact among 
many others who support this hypothesis is that abscopal effects 
cannot be observed for mice deficient in functional adaptive 
immune cells (10).
Generally, radiation might change the tumor cell phenotype 
and/or the tumor microenvironment. Tumor cells increase the 
surface expression of immunogenic molecules, including adhe-
sion molecules, death receptors, stress-induced ligands, cryptic 
antigens, and stimulatory molecules, such as MHC-I and CD80, 
thereby becoming more sensitive to T cell-mediated cytotoxicity. 
Additionally, in the tumor microenvironment, pro-inflammatory 
molecules and danger signals increase (11–13). Immune cells 
are recruited into the tumor and should be stimulated by 
additional immune modulation (14). Radiation regimens have 
to be improved and adjusted to maximize immunostimulatory 
functions for successful combination with other treatments, 
including IT.
Colorectal cancer is the third most commonly diagnosed 
malignancy and the fourth leading cause of cancer-related deaths 
worldwide and forms malignant cells in the tissues of the colon or 
rectum (15). Extensive efforts to improve the clinical management 
of patients with colorectal cancer have been made, but approved 
treatments only offer limited survival benefit. Therefore, alterna-
tive therapeutic strategies such as radioimmunotherapy need 
to be explored with preclinical animal models (16, 17). It has 
already become evident that the immune infiltrate including type, 
density, and location of immune cells within human colorectal 
tumors predict clinical outcome such that individuals with higher 
infiltrations of T cells have increased survival independent of the 
disease stage (18).
We investigated the dynamics of immune cell infiltration 
into colorectal tumors after local hypofractionated irradiation 
to define optimal time points for additional immune modula-
tions and radiation breaks to protect the infiltrating immune 
cells. We used the carcinogen-induced murine colon carcinoma 
CT26 colon adenocarcinoma model for our examinations (19) 
as responses to immune modulations are similar to those in 
humans (20).
MaTerials anD MeThODs
cell culture
Mouse colon adenocarcinoma cell line CT26.WT (CT26 cells) 
was cultured in RPMI 1640 (with stabile glutamine) supple-
mented with 10% fetal bovine serum (FBS), 100 U/ml penicillin, 
and 100 μg/ml streptomycin (subsequently referred to as R10). 
CT26 cells tested negatively for mycoplasma contamination were 
maintained in a 5% CO2 atmosphere at 37°C and 95% relative 
humidity to achieve optimal cell growth. All cell culture methods 
were performed in laminar flow hoods to avoid microbiological 
contamination.
Treatment of cT26 cells and cell Death 
analyses
The 3 ×  106  CT26 cells were seeded in 75  cm2 culture flasks, 
supplied with R10, and after achieving adherence, treated with 
ionizing radiation with a single dose of 5 Gy (120 kV, 22.7 mA; 
Isovolt Titan, GE Inspection Technologies, Hürth, Germany). 
Mock treated CT26 cells served as controls. After 24  h of 
incubation, the supernatants (SN) were collected, centrifuged 
(350 g, 5 min, room temperature) to remove remaining cells and 
stored at −80°C. Subsequent adherent cells were washed with 
PBS and detached with accutase (Sigma-Aldrich, Steinheim, 
Germany). Afterward, the cells were centrifuged (350 g, 5 min, 
room temperature) and the cell pellet (together with the pellet 
from the SN centrifugation) was resuspended in R10. For analy-
sis of cell death, 1 × 105 cells were transferred in 400-μl Ringer 
solution containing 0.2  mg AnxA5-FITC (Life Technologies, 
GeneArt, Regensburg, Germany) and 0.4 mg PI (Sigma-Aldrich, 
Munich, Germany). After 30 min incubation at 4°C in the dark, 
flow cytometry was conducted. Double negative (AnxA5−/PI−) 
cells were defined as viable, AnxA5+/PI− cells were defined as 
apoptotic, and double positive (AnxA5+/PI+) cells were defined 
as necrotic.
colony Formation assay
CT26 tumor cells were plated in triplicates in 60-mm dishes 
(Nunc Thermo Fisher, Waltham, MA, USA) at concentrations 
estimated to yield approximately 100 colonies/dish. Then, the 
cells were treated with irradiation of 1 ×  5  Gy or 2 ×  5  Gy. 
After incubation for approximately 2 weeks, the cells were fixed 
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and adherent cells were stained with methylene blue (Sigma-
Aldrich, Munich, Germany) for 30 min. Colonies with >50 cells 
were scored.
generation of Dendritic cells (Dcs) from 
Mouse Bone Marrow
Generation of DCs from mouse bone marrow was performed 
according to Lutz et al. (21). At day 0, femurs and tibiae of 8- to 
10-week-old female BALB/c mice were removed and purified 
from surrounding skin and muscle tissue. For disinfection, 
intact bones were left in 70% ethanol for 5  min and were 
washed with RPMI 1640 afterward. Subsequently, the articular 
heads of each bone were cut off and the bone marrow was 
flushed out. After cell clusters had been disintegrated, the cell 
suspension was centrifuged (350 g, 5 min, room temperature). 
Then, the cell pellet was resuspended in R10 supplemented 
with β-mercaptoethanol (0.05mM) and freshly added 200  U/
ml mouse GM-CSF (referred to as DC medium). Cells were 
counted and 2 × 106 bone marrow leukocytes were seeded per 
100  mm PS bacteriological Petri dish (Falcon®, Corning, NY, 
USA) containing 10 ml DC medium. At day 3, 10 ml fresh DC 
medium was added per plate. At days 6 and 8, half of the SN per 
plate was collected and centrifuged. Thereafter, the cell pellet 
was resuspended in 10 ml fresh DC medium and returned to the 
plate. At day 10, DCs were harvested.
Transwell Migration assay and analyses  
of activation of Dcs
At day 10 of DC cultivation, DCs were harvested, counted, 
and adjusted to 1.25 ×  106  DCs/ml DC medium. SN from the 
irradiated CT26 cells were thawed on ice and, afterward, 1.5 ml 
SN per approach was placed in the bottom of a well of a six-
well plate (Greiner Bio-One, Frickenhausen, Germany). A cell 
permeable membrane (with 3.0-μm pore size; Greiner Bio-One, 
Frickenhausen, Germany) was attached to each well and 800-μl 
DC cell suspension (containing 1 × 106 cells) was transferred on 
the upper side of the membrane. The six-well plates were stored 
in a cell incubator at 37°C overnight (14 h).
For analysis by flow cytometry, migrated cells had to be 
collected. Therefore, each membrane was carefully lifted with 
tweezers, and the bottom side was washed with cell suspen-
sion of the respective well to collect these cells. Then, the cell 
suspension was collected from each well and strongly adherent 
cells were removed by rinsing the well with cold PBS. After 
centrifugation, each cell pellet was resuspended in Fc block 
solution [PBS, 10% inactivated FBS, 0.001% Fc-Block, CD16/32 
(ebioscience, Frankfurt, Germany)] and incubated for 10 min at 
4°C in the dark to prevent non-specific binding of antibodies to 
Fc receptors.
Cell suspension was distributed to three 1.4  ml PP tubes 
(Micronic, AR Lelystad, The Netherlands) and antibody solution 
[MHCII-e450 (0.4  μg/ml, eBioscience, Frankfurt, Germany), 
CD80-PE (0.4 μg/ml, BD Pharmingen, New York, NY, USA), and 
CD86-Alexa® Fluor700 (0.4 μg/ml, BD Pharmingen. New York, 
NY, USA) diluted in FACS buffer (PBS, 2% inactivated FBS)] was 
added. After incubation for 30 min at 4°C in the dark, cells were 
washed with FACS buffer and resuspended in it. Further, SN 
were also directly added to DCs and the expression of the activa-
tion markers CD80 and CD86 was analyzed similarly 24 and 
48 h afterward. Cells were analyzed by flow cytometry (Gallios, 
BeckmanCoulter Inc., Krefeld, Germany), and the number 
of MHCII+ cells was defined as the number of migrated DCs. 
Gating on MHCII+ cells was performed for analysis of the mean 
fluorescence intensity of cells stained with maturation markers 
CD80 and CD86.
animal studies
The animal studies were approved by the “Regierung von 
Mittelfranken” and conducted according to the guidelines of the 
Federation of European Laboratory Animal Science Associations 
and the “Gesellschaft fuer Versuchstierkunde.” The BALB/c mice 
(Janvier Labs, Le Genest-Saint-Isle, France) were kept under 
controlled SPF conditions of humidity (55 ± 5%), temperature 
(22 ± 2°C), 12/12-h light–dark cycles and received a special diet 
and water ad libitum.
injection of cT26 cells and Measurement 
of Tumor growth
Before injection of CT26 cells in BALB/c mice, the colon 
adenocarcinoma cells were harvested and washed twice with 
Ringer solution. Thereafter, CT26 cells were counted with the 
Neubauer-improved counting chamber and percentage of dead 
cells was determined using trypan blue staining. Concentration 
was adjusted to 4 × 106 viable CT26 cells/ml Ringer solution. Mice 
were anesthetized with isoflurane, and injection of 1.2 × 106 CT26 
cells in 300-μl Ringer solution was administered subcutaneously 
in the shaved, disinfected right flank. Tumor width and length 
were measured using a digital caliper with a measurement 
accuracy of 0.1 mm and tumor volume was calculated accord-
ing to the following formula (22): volume (mm3) = 0.5 × width2 
(mm2) × length (mm).
Treatment of cT26 Tumors with rT
At days 8 and 12 after tumor cell injection, local irradiation of 
the tumor was performed. For this, three mice that had been 
anesthetized with isoflurane were placed into a purpose-built 
Plexiglas® (Evonik Industries AG, Darmstadt, Germany) box at a 
time and inhalation anesthesia was maintained during the whole 
process to prevent movement of the mice. Tumors were irradiated 
with a dose of 5 Gy each day using a linear accelerator unit with 
6 MV and a focus-skin distance of 1,000 mm. In order to protect 
healthy tissue, the gantry of the linear accelerator was rotated to 
340° as previously described by our group (23).
Tumor resection and Blood samples
For tumor resection, terminal isoflurane anesthesia of mice was 
applied. At each indicated time point, tumors of three animals 
were independently analyzed. Blood samples were taken by 
cardiac puncture and were transferred into heparinized micro-
tainer tubes (BD Microtainer, New York, NY, USA) immediately 
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thereafter. Following centrifugation (12,000  g, 10  min, room 
temperature), to separate serum from cellular components, mice 
sera were transferred into reaction tubes and stored at −20°C 
until further usage.
Tumor Dissociation Procedure
Tumor dissociation was conducted with the mouse tumor dis-
sociation kit (Miltenyi Biotec, Bergisch Gladbach, Germany) 
according to manufacturer’s instructions with minor modifica-
tions. In brief, following removal, tumors were cut into 2–4 mm 
pieces and transferred immediately into tubes containing 
the enzymatic mix. Tubes were placed on the gentleMACS™ 
Dissociator (Miltenyi Biotec, Bergisch Gladbach, Germany) 
and the predissociation program was run. After incubation for 
40  min at 37°C, the final dissociation program was executed. 
Cell suspension was then pipetted through a 70-μm cell strainer 
into a 50 ml tube. Subsequent to centrifugation (300 g, 7 min, 
room temperature), the cell pellet was resuspended in RPMI 
1640, and cells were counted using the Neubauer improved 
hemocytometer.
Measurement of Tumor-infiltrating 
immune cells
After centrifugation (300  g, 7  min, room temperature), cells 
were resuspended in Fc block buffer and incubated for 10 min 
at 4°C. Cell suspensions were distributed into 1.4 ml PP tubes 
and for panel 1 [CD4-FITC (0.5 μg/ml, BD Pharmigen, New 
York, NY, USA), CD8a-PE (1:500, Miltenyi Biotec, Bergisch 
Gladbach, Germany), NK 1.1-APC (1:500, Miltenyi Biotec, 
Bergisch Gladbach, Germany)], panel 2 [CD11b-FITC (0.5 μg/
ml, BD Pharmigen, New York, NY, USA), F4/80-Alexa Fluor®647 
(1:500, Invitrogen, Darmstadt, Germany), LY-6G(GR1)/
LY-6C-V450 0.4 μg/ml, BD Horizo, New York, NY, USA], and 
panel 3 [MHC class II(I-A/I-E)-eFluor®450 (0.4 μg/ml, eBio-
science, Frankfurt, Germany)], staining solutions were added. 
After incubation for 30 min at 4°C in the dark, cells were washed 
with FACS buffer and resuspended in FACS buffer [containing 
7-AAD (BioLegend, San Diego, CA, USA, 1:500) for exclu-
sion of necrotic cells]. After staining, infiltrated immune cells 
were detected using flow cytometry. Gating was performed 
on 7-AAD negative (non-necrotic) cells. The percentage of 
positive cells was determined for each cell marker or for com-
binations of various markers. Detection of regulatory T  cells 
(Tregs) (panel 4) was performed as follows: cell suspension was 
incubated with CD4-VioBlue® (1:40, Miltenyi Biotec, Bergisch 
Gladbach, Germany) and CD25-Alexa Fluor®488 (2.5 μg/ml; 
eBioscience, Frankfurt, Germany) for 10 min at 4°C in the dark. 
Thereafter, 500 μl FACS buffer (PBS containing 2% FCS) was 
added and cells were centrifuged (350 g, 5 min, 4°C). The cell 
pellet was resuspended in fixation/permeabilization solution 
and incubated for 30 min at 4°C in the dark. Cells were washed 
with FACS buffer and then with permeabilization solution. 
Afterward, cells were resuspended in permeabilization buffer. 
Following incubation for 5  min at 4°C, FoxP3-APC antibody 
(1:40, Miltenyi Biotec, Bergisch Gladbach, Germany) was added 
and incubated for 30 min at 4°C in the dark. Finally, cells were 
washed with permeabilization buffer and the cell pellet was 
resuspended in FACS buffer.
analysis of Tumor cell-specific igM 
antibodies in sera of cT26 colon  
Tumor-Bearing Mice
For determination of tumor cell-specific IgM antibodies, 
indirect immunofluorescence analysis was used. Mice sera 
were thawed on ice and 1  μl of the respective serum sample 
was co-incubated with 1 × 105 viable CT26 cells for 1 h at 4°C. 
Thereafter, cells were washed with PBS/10% FBS. The amount 
of bound antibodies was analyzed by adding staining solution 
[5.8 μg/ml FITC-conjugated goat anti-mouse IgM (Invitrogen, 
Darmstadt, Germany)] for 1 h at 4°C in the dark. After washing, 
cells were resuspended in PBS/10% FBS. Using flow cytometry, 
the mean fluorescence intensity of CT26 cells per sample was 
analyzed and equated with the tumor cell-specific IgM antibody 
level in the serum.
Flow cytometry
For cell death analysis, analysis of migrated cells in the transwell 
migration assays, detection of IgM antibodies, and for investi-
gation of immune cell infiltration in CT26 colon tumors, flow 
cytometry using GalliosTM and Epics XL MCL was conducted. 
Both flow cytometers were equipped with a multi-carousel 
loader unit that made it possible to analyze up to 32 samples 
automatically in a row. Coulter® Isoton® II diluent functioned 
as sheath fluid in all experiments. Flow cytometry data were 
acquired as LMD files, which were analyzed using Kaluza 1.2 
software.
resUlTs
hypofractionated rT reduces colony 
Formation and generates apoptotic and 
necrotic cT26 Tumor cells
We first tested in  vitro whether irradiation with a single dose 
of 5 Gy and repeated irradiation with 2 × 5 Gy (hypofraction-
ated RT) succeeds to reduce the colony formation of colorectal 
cancer cells and also induces immunogenic cell death forms. 
Both a single irradiation dose with 5 Gy and a hypofractionated 
irradiation dose significantly reduced the colony formation of 
CT26 cells (Figure 1A). However, a second irradiation dose of 
5 Gy is needed to significantly increase the percentage of apop-
totic and necrotic tumor cells as early as 1 day after treatment 
(Figure 1B).
sn of Tumor cells induce Migration and 
sn of irradiated Tumor cells increase 
activation of Dcs In Vitro
To further characterize the immunostimulatory potential of the 
irradiated tumor cells, a transwell migration assay was performed 
with murine DCs (mDCs) (Figure 2). The transmigration as well 
as the activation status of the migrated DCs was analyzed. SN 
FigUre 1 | hypofractionated irradiation reduces the colony formation 
and induces apoptosis and necrosis of cT26 cells. The colony formation 
was determined by standard colony formation assay (a). After incubation for 
approximately 2 weeks, the cells were fixed and colonies with >50 cells were 
scored. The cell death analyses were performed 24 h after single or double 
irradiation of CT26 colorectal tumor cells with 5 Gy. Cell death was 
determined by flow cytometry; apoptotic cells (gray) are defined as AxV+/PI−  
cells and necrotic (black) as AxV+/PI+ cells (B). Joint data of three 
independent experiments, each performed in duplicates, are presented as 
mean ± SEM and analyzed by Student’s t-test; **p < 0.01.
FigUre 2 | Dendritic cells (Dcs) migrate toward supernatants (sn) of 
cT26 cells and are particularly activated by sn of irradiated cT26 
cells. Bone marrow-derived DCs from BALB/c mice (mDCs) were harvested 
and seeded to the upper chamber of a transmigration system (3.0 μm pore 
size). The lower chamber was filled with cell culture SN obtained from CT26 
tumor cells 24 h after irradiation with 2 × 5 Gy on consecutive days or with 
SN of mock-treated cells. After 14 h of incubation at 37°C, the transmigration 
index (MI), reflecting the migration of mDCs toward SN of the tumor cells 
versus the medium only control, was determined (a) and the expression of 
CD80 (B) and CD86 (c) on the MHCII+ transmigrated cells was determined 
by flow cytometry. Joint data of three independent experiments are presented 
as mean ± SEM and analyzed by Student’s t-test; **p < 0.01.
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of tumor cells attracted mDCs resulting in over 1.5× more cells 
migrating through the insert compared to the medium control. 
However, this was independent of whether the cells were irradi-
ated or not (Figure 2A). However, only SN of the irradiated tumor 
cells induced a significant higher increase in the percentage of 
migrated mDCs showing enhanced expression of the activation 
markers CD80 and CD86 compared to mock treated and medium 
controls (Figures  2B,C). To test whether mDCs are activated 
through the process of (trans)migration or by the SN per  se, 
mDCs were also directly incubated with SN of mock treated and 
irradiated tumor cells, respectively. As shown in Figure 3, SN of 
irradiated CT26 cells induced a significant increased expression 
of the activation markers CD80 and CD86 on mDCs compared 
to SN of the mock treated control. This was observed 24 and 
48 h after incubation with the SN (Figures 3A,B). However, the 
increased expression of CD80 and C86 on mDCS induced by SN 
of irradiated CT26 cells was weaker compared to that induced by 
lipopolysaccharide (Figure 3).
FigUre 3 | The activation of dendritic cells (Dcs) by supernatants 
(sn) of irradiated cT26 cells is independent of the migration. Bone 
marrow-derived DCs from BALB/c mice (mDCs) were incubated at 37°C in 
SN obtained from CT26 tumor cells 24 h after irradiation with 2 × 5 Gy on 
consecutive days, in SN of non-irradiated mock treated CT26 cells, or in 
medium containing lipopolysaccharide (LPS). The expression of CD80 (a) 
and CD86 (B) on mDCs was analyzed after 24 and 48 h via flow cytometry. 
Representative data of one out of three independent experiments each 
performed in triplicates are presented as mean ± SEM and analyzed by 
Student’s t-test; **p < 0.01.
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in the box and during the whole irradiation procedure. On 
day 8 after the injection of CT26 tumor cells in BALB/c mice, 
the mice were irradiated with 2 ×  5  Gy in a 4-day interval. 
Beginning with the day of the first irradiation, the tumor vol-
ume was measured daily for 14 days (Figure 4B). The treatment 
of tumor-bearing mice with hypofractionated RT delayed the 
tumor growth significantly and resulted in good local tumor 
control (Figure 4C).
infiltration of immune cells into the 
irradiated Tumor Occurs in a narrow  
Time Frame
Next, we were interested whether hypofractionated irra-
diation induces immune cell infiltration into the tumor and, 
in particular, the chronology of this process. Each day of the 
observation period three mice per group were sacrificed for 
the analysis of tumor-infiltrating leukocytes. Elevated numbers 
of tumor-infiltrating macrophages (CD11b high/F4-80+) and 
antigen-presenting cells (MHC-II+) between day 5 and 10 after 
the first irradiation were observed in tumors of irradiated mice 
compared to mock treated tumors (Figures 5A,B). The amount 
of CD8+ T cells in irradiated tumors did not differ from that of 
mock-treated tumors, except at day 8, where significantly more 
cytotoxic T cells were present in irradiated tumors (Figure 5C). 
CD4+ T cells migrated into non-irradiated and irradiated tumors 
in a similar manner (data not shown). The percentage of Treg 
(CD4+/CD25+/FoxP3+) in the tumor was low and irradiation 
with 2 × 5 Gy induced no higher amounts of Treg when compared 
to the normal turnover in non-irradiated tumors (Figure 5D). 
The same was observed for myeloid-derived suppressor cells, 
defined as CD11b+/Gr-1+ cells (Figure  5E). Starting at day 9 
after the first irradiation, the amount of immune cells did not 
differ any more between irradiated compared to mock-treated 
tumors (Figure 5).
hypofractionated irradiation induces 
Tumor cell-specific igM antibodies
To test whether irradiation also affects humoral immune response, 
tumor cell-specific IgM antibodies were analyzed. For this, blood 
samples of tumor-bearing mice were taken and the gained 
serum was co-incubated with CT26 tumor cells. The amount of 
bound antibodies was analyzed by adding FITC-conjugated goat 
anti-mouse IgM F(ab’)2 fragments (Figure 6A). The analyses by 
flow cytometry showed that the titer of tumor cell-specific IgM 
antibodies was significantly higher compared to mock-treated 
animals only in serum of mice whose tumor had been irradiated 
(Figure 6B).
DiscUssiOn
Neoadjuvant chemoradiation has been shown to alter the in situ 
immune cell population in rectal cancer. A high CD8+ T  cell 
density in the stroma after RCT was associated with a favorable 
clinical outcome (24). In colorectal cancer, the density of infiltra-
tion of lymphocytes is associated with better overall survival and 
the immune status has emerged as a beneficial tool to improve 
local Tumor control of cT26 Tumors  
in BalB/c Mice can Be achieved with 
2 × 5 gy hypofractionated irradiation
To irradiate the tumor-bearing BALB/c mice, we manufactured 
a Plexiglas® box, which allows the irradiation of three mice at 
once (Figure 4A). The tumors were locally irradiated (colored 
dose distribution area; Figure 4A) and treatment planning was 
conducted using a computer tomography image of the Plexiglas 
irradiation box and tumor-bearing mice with Philips pinnacle 
software (Best, Netherlands). To protect normal tissue (body of 
the mouse 1, 2, and 3), the gantry of the linear accelerator was 
rotated to 340° and the tumor area was then irradiated with 
a dose of 5 Gy with 6-MV photons and a focus-skin distance 
of 1,000 mm. The mice were anesthetized before placing them 
FigUre 4 | hypofractionated radiotherapy (rT) results in local control of cT26 colon cancer tumors in BalB/c mice. The planning of the irradiation was 
conducted using a computer tomography image of the irradiation box and tumor-bearing mice with Philips pinnacle software to obtain an optimal target volume. 
Afterward, the dosimetry of the irradiation was performed manually with a calibrated ionization chamber. To further protect the normal tissue, the gantry of the 6-MV 
linear accelerator was rotated to 340°. Tumors of three anesthetized mice can be irradiated locally at once and the dose distribution (colored areas) shows that only 
the tumor and not the rest of the mouse is exposed to radiation (a). The tumor volumes were determined daily. Up to day 4 after the first irradiation with 5 Gy, the 
infiltration of immune cells in the tumors was monitored in tumors of three mice from each group (B). Hypofractionated irradiation with 2 × 5 Gy resulted in good 
tumor control (c); *p < 0.05, **p < 0.01; n: variable: at the starting point n = 40, with three mice less each following day per treatment group.
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the management of patients (25). Immunological biomarkers are, 
therefore, being used more frequently as a tool for the prediction 
of prognosis and response to therapy in addition to traditional 
tumor staging (26). However, it is important to consider the spati-
otemporal dynamics of different immune cell types that infiltrate 
into tumors (27).
Currently, several combinations of RT with IT, such as 
monoclonal antibodies blocking immune checkpoints are 
being tested in clinical trials, since it is still unknown how to 
bring these treatment modalities together chronologically to 
achieve the most beneficial outcome for the patient (28). As a 
prerequisite to coordinate both treatments, it is mandatory to 
know the RT-induced immune profile, which can be boosted 
and harnessed by IT. Therefore, we investigated the infiltra-
tion of immune cells into irradiated colorectal cancer tumors 
(Figure 5).
Hypofractionated irradiation with 2 × 5 Gy induced a signifi-
cant increased infiltration of cells of the innate immune compart-
ment. Enhanced APCs (macrophages and MHC class II positive 
cells referred to as DCs) as early as 1 day after the last irradiation 
were observed. Of note is that the amount of APCs was increased 
in the CT26 colorectal cancer tumor only after about 3 days.
Our in vitro experiments revealed that irradiation of the colo-
rectal tumor cells with 2 × 5 Gy results in a mixture of apoptotic 
and necrotic tumor cells and in recruitment and activation of 
DCs (Figures 1–3). Danger signals released by tumor cells might 
be central for the recruitment of myeloid cells in the tumor (29). 
While DCs did migrate in  vitro similarly toward SN of mock 
treated and irradiated tumor cells, in particular SN of irradiated 
tumor cells induced an increased expression of the activation 
markers CD80 and CD86 on DCs. One could speculate that 
low amounts of danger signals being present under tumor cell 
culture conditions suffice to recruit DCs and that higher amounts 
of them being present after irradiation are mandatory to induce 
an increased expression of activation markers on DCs. High 
amounts of the danger signal Hsp70 in the extracellular milieu 
have already been demonstrated to induce an increased expres-
sion of CD80 and CCR7 on DCs (30).
In vivo, when the APCs dropped again, CD8+ T  cells were 
enhanced in the tumor, but stayed there only for around 1 day 
(Figure  5). This might indicate that the cytotoxic T  cells were 
recruited by the activated APCs. Klug and colleagues have previ-
ously demonstrated that gamma irradiation causes normaliza-
tion of aberrant vasculature in tumors and fosters infiltration 
of immune cells. This was dependent on reprogramming of 
macrophages (31). Since normalization of the tumor vasculature 
seems to be a key factor for enhanced immune cell infiltration, 
these effects can only be observed in vivo and not with in vitro 
model systems. We also did not observe any differences in the 
migration index of DCs toward SN of non-irradiated compared 
to SN of irradiated CT26 cells in our in  vitro migration assay 
(Figure 2).
Recently, it was shown that hypofractionated irradiation 
of B16 melanoma tumors with 2 ×  12 Gy on consecutive days 
FigUre 5 | The infiltration of immune cells in irradiated tumors is timely restricted. At each day of the examination period, three tumors of each group 
were separately enzymatically dissociated and consecutively analyzed for immune cell infiltration by flow cytometry. The amount of the indicated immune cells 
out of all analyzed viable cells is displayed (a–e). Data of three independent tumors are presented as mean ± SEM and analyzed by Student’s t-test; *p < 0.05, 
**p < 0.01.
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induced a high infiltration of CD8+ T cells at day 5 after the last 
irradiation. Later on, the amount of the cytotoxic T cells dropped 
again (32). Our data also reveal that CD8+ T cells do migrate in 
solid tumors that have been irradiated with a hypofractionated 
protocol. It must be emphasized that the immune cell infiltration 
takes place in a narrow time window (Figure 5). This knowledge is 
indispensable for designing strategies for inclusion of additional 
IT to classical tumor therapies, namely RT, CT, or RCT.
It has become clear that RT and RCT do have the potential 
to change the tumor and its microenvironment (33) and that 
radiation exposure is reflected locally and systemically (34). 
Innovative IT approaches should consider the dynamics of 
FigUre 6 | hypofractionated irradiation of colorectal tumors induces 
tumor-cell-specific igM antibodies. The sera of the mice whose tumor 
had been irradiated with 2 × 5 Gy were analyzed for tumor cell-specific IgM 
antibodies. For this, serum was collected from blood samples taken at the 
last day of the observation period (see Figure 3). These sera were then 
co-incubated with viable CT26 cells. IgM antibodies bound to the tumor cells 
were stained with FITC-conjugated anti-mouse IgM F(ab’)2 fragments and 
analyzed via flow cytometry (a). Data of three independent tumor-bearing 
mice are presented as mean ± SEM (B) and analyzed by Student’s t-test; 
**p < 0.01.
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radiation-induced immune cell infiltration into tumors since 
the immune cells should be activated in the modified environ-
ment. Further, hypofractionated radiation might be of advan-
tage in radioimmunotherapy since wide intervals between the 
single irradiations do exist that might allow the immune cells 
to act and react (35). In particular, cytotoxic T cells and B cells 
do have a radiation sensitive phenotype and might be affected 
when being present in the tumor during re-irradiation (36). 
The infiltration of immune suppressive cells such as Treg and 
MDSC was not significantly influenced by hypofractionated RT 
(Figure 5). However, a slight increase of Treg was seen at days 
8–10 after the first irradiation and, therefore, mainly following 
the infiltration of CD8+ T cells. An optimal re-irradiation of the 
tumor would in this case be at day 9–10 where the cytotoxic 
T cells have already left and immune suppressive Treg cells are 
still inside the tumor.
While in many cases it has been demonstrated that the 
cellular component of the adaptive immune system and, 
in particular, CD8+ T  cells is key for radioimmunotherapy-
induced antitumor immune responses, much less is known 
about the humoral part (37). We found tumor cell-specific IgM 
antibodies to be enhanced in the serum of mice whose tumors 
had been irradiated with 2 × 5 Gy (Figure 6). Splenocytes of 
mice whose renal cancer tumor was treated with radioim-
munotherapy secreted higher amounts of tumor cell-specific 
IgM antibodies, indicating that a systemic antitumor immune 
response was triggered (38). We show for the first time that 
hypofractionated RT per  se might be sufficient to provoke 
such humoral antitumor responses. However, the latter are not 
necessarily involved in abscopal radiation responses, as it has 
recently been demonstrated with the 67NR mammary carci-
noma model and hypofractionated irradiation with 3 × 8 Gy. 
However, increased IgM was also observed in the irradiated 
primary tumor (39).
We conclude that hypofractionated RT in vivo attracts immune 
cells into colorectal cancer tumors and is capable of inducing a 
tumor cell microenvironment that activates DCs. The infiltration 
of the immune cells is dynamic and, therefore, timely restricted. 
Cytotoxic CD8+ T  cells follow the APCs. This knowledge is 
valuable for designing multimodal radioimmunotherapies: at 
days of high infiltration of immune cells being involved in anti-
tumor immune responses, RT should be paused and IT should 
be applied. Consequently, at days of low infiltration of these 
immune cells and high infiltration of immune suppressive cells, 
re-irradiation without IT should be performed. Knowledge of 
how immune cells in the periphery correlate with the observed 
processes in the tumor will further facilitate the optimization of 
multimodal radioimmunotherapies (40). The potential syner-
gies of RCT with IT should be exploited to improve the clinical 
outcome for each patient (41), and the preclinical data presented 
here on the chronology of immune cell infiltration into tumors 
after local irradiation should help to optimize of clinical radioim-
munotherapy protocols.
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